IP Library Granted Patent US 7,691,808
Granted Patent B2
US 7,691,808 · App. 11/516,874 · Granted Apr 6, 2010

Use of Slurp-1 for treating diseases related to acetylcholine receptor dysfunction

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,691,808
App. No.
11/516,874
Granted
Apr 6, 2010
Kind
B2
Abstract

Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders. Also disclosed are compositions and methods for the treatment or prevention of skin pathologies. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. Antibodies generated against SLURP-1 and related proteins are also included.

Claims (7)

1. A method for treating pain in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising the amino acid sequence of SEQ ID NO: 2, thereby treating pain in the subject.

2. A method for treating pain in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide comprising amino acids 23-103 of the amino acid sequence of SEQ ID NO: 2, thereby treating pain in the subject.

3. The method of claim 2 , comprising administering to the subject an effective amount of a SLURP-1 polypeptide consisting of amino acids 23-103 of SEQ ID NO: 2.

4. A method for treating pain in a subject suffering therefrom, the method comprising administering to the subject an effective amount of a SLURP-1 polypeptide at least 95% identical to the amino acid sequence of SEQ ID NO: 2 and wherein the polypeptide enhances the amplitude of acetylcholine-evoked macroscopic currents, thereby treating pain in the subject.

5. The method of claim 4 , wherein the SLURP-1 polypeptide is at least 99% identical to the amino acid sequence of SEQ ID NO: 2.

6. The method of claim 1 , 2 , 3 , 4 , or 5 , wherein the effective amount of the SLURP-1 polypeptide is from about 1.0 pM to about 10 μM.

7. The method of claim 1 , 2 , 3 , 4 , or 5 , wherein the effective amount of the SLURP-1 polypeptide is administered to the subject by a method selected from the group consisting of orally, intravenously, intraperitoneally, intranasally, and intramuscularly.

Assignments (5)
CHANGE OF NAME Recorded Dec 4, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023603/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2006
From: LAUSANNE, UNIVERSITY OF; GENEVE, UNIVERSTIY OF
To: APPLIED RESEARCH SYSTEMS ARS
Reel/Frame 018625/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2006
From: HOGG, RONALD; BERTRAND, DANIEL
To: GENEVA, UNIVERSITY OF
Reel/Frame 018592/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 8, 2006
From: CHIMIENTI, FABRICE; HUBER, MARCEL; HOHL, DANIEL
To: UNIVERSITY OF LAUSANNE
Reel/Frame 018592/0602 →